Procaps Group Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Procaps Group.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 23.7% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively
Mar 28Is Procaps Group S.A. (NASDAQ:PROC) Worth US$3.7 Based On Its Intrinsic Value?
Feb 02Calculating The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)
Feb 01Procaps Group reports Q2 results
Aug 30Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)
Jan 10In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Procaps Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2023 | 414 | 52 | 34 | 63 | N/A |
6/30/2023 | 406 | 67 | -7 | 21 | N/A |
3/31/2023 | 408 | 33 | -22 | 11 | N/A |
12/31/2022 | 410 | 43 | -17 | 14 | N/A |
9/30/2022 | 435 | 60 | -22 | 8 | N/A |
6/30/2022 | 431 | -73 | 7 | 37 | N/A |
3/31/2022 | 418 | -67 | 9 | 34 | N/A |
12/31/2021 | 410 | -101 | 13 | 37 | N/A |
9/30/2021 | 401 | -119 | 58 | 92 | N/A |
6/30/2021 | 374 | -9 | 39 | 60 | N/A |
3/31/2021 | 342 | -18 | 49 | 67 | N/A |
12/31/2020 | 331 | -10 | 53 | 71 | N/A |
1/1/2020 | 325 | -17 | 56 | 68 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if PROC's forecast earnings growth is above the savings rate (2.5%).
Earnings vs Market: Insufficient data to determine if PROC's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if PROC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if PROC's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if PROC's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PROC's Return on Equity is forecast to be high in 3 years time